New data presented at the American Society of Retina Specialists 2024 examine the benefits and adverse event profiles of two ...

Afqlir is indicated to treat various retinal diseases, including neovascular age-related macular degeneration (nAMD) ...

AlloVir has entered into a definitive agreement for the acquisition of the complete outstanding shares of Kalaris ...

Peking University researchers have developed a deep learning-based, noninvasive choroidal angiography method that enables ...

Neuralink Corp., Elon Musk’s brain-computer venture, and rivals like Science Corp. are making strides in technology that ...

Sandoz (SDZNY) said that the European Commission has granted marketing authorization for Afqlir (aflibercept) 2 mg vial kit and ...

Researchers at Johns Hopkins University have identified a process in the eye that may explain why biologic drugs for treating ...

Sandoz (SDZNY) announced that the European Commission, or EC, has granted marketing authorization for Afqlir 2 mg vial kit and pre-filled ...

Sandoz's approval of Afqlir highlights their commitment to affordable, effective treatment options for retinal diseases.

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window GA lesions, which form on the retina due to degeneration of pigment epithelium and photoreceptors, significantly impact ...

EyePoint Pharmaceuticals' lead product, EYP-1901, shows promising phase 2 results for wet AMD and DME. Read more about EYPT ...